explore -WSS

explore

author：explore 2025-10-02 20:49:51 - browse：9

IQVIA signage. -- health tech coverage from STAT — Adobe

The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： David Sabatini, ex

WSS

Positive childhood experiences can help future health

AstraZeneca to buy developer of next

U.K. researchers warn about biases in medical devices, algorithms

World's first CRISPR

Readout Newsletter: Bluebird, CVS, Contineum

Intermittent fasting comes with a heart risk? Not so fast

entertainment

explore

focus

How to save PrEP access — and even expand it

Ransomware attacks on hospitals: Study outlines patient impact

Walensky prepares to leave CDC — and Congress — behind

Positive childhood experiences can help future health

New air purifier tech could be key to improving indoor air quality

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Trump demands the U.S. pay no more for drugs than other countries … again

Hospitals look to new technology to keep health care workers safe

Cancer drug shortages should be causing more outrage

A daunting task: navigating dual Medicare, Medicaid eligibility

Wikipedia

AstraZeneca to buy developer of next

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Orchard's therapy for neuron disease in children wins FDA approval

A daunting task: navigating dual Medicare, Medicaid eligibility

Methadone treatment changes are coming. Do they go far enough?

hotspot

focus

Wikipedia

hotspot